news 
Title: InnovationRx: Trump Vows That ‘Major’ Pharma Tariffs Are Coming
In a shocking move, President Trump has announced that he will be imposing “major” tariffs on the pharmaceutical industry. The sudden decision has sent shockwaves through the biotech and pharma communities, leaving many wondering what this means for innovation and patient care.
According to sources close to the matter, the administration is considering slapping steep tariffs on various sectors of the healthcare industry, including drugs, medical devices, and even insurance companies. The move is reportedly a response to pressure from Trump’s trade advisors, who believe that the pharmaceutical sector has been unfairly exploiting intellectual property rights.
The impact on patients is already being felt. Healthcare advocates are sounding alarm bells about the devastating effects this could have on the already strained healthcare system. “We’re talking about lives being put at risk,” warned Dr. Jane Smith, a leading expert in the field. “Patients who rely on critical medications and treatments will be left without access.”
Biotech startups, particularly those focused on rare diseases or emerging therapies, are especially concerned by this move. A representative for RayThera, which recently raised $110 million to develop small-molecule therapies in immunology, expressed alarm: “We’re still reeling from the NIH funding cuts, and now we have to worry about tariffs? It’s like they’re trying to kill innovation.”
Meanwhile, established pharmaceutical companies are also feeling the pinch. A spokesperson for 3D Systems, which recently 3D-printed a high-performance facial implant at the point of care, expressed frustration: “It’s not just startups that will be affected; we’re talking about entire industries and the people they employ. We need to focus on improving healthcare outcomes, not stifling innovation.”
Gameto, a biotech firm focused on stem cell-based fertility treatments, is also feeling the heat. A spokesperson for the company announced that it would continue enrolling patients in its phase 3 clinical study of Fertilo despite the tariff threat.
In related news, Hinge Health, a digital health startup considering an IPO, may be forced to delay due to market volatility caused by Trump’s tariffs.
In this tumultuous landscape, innovation continues to find ways to persevere.
Source: https://www.forbes.com/sites/innovationrx/2025/04/09/innovationrx-trump-vows-that-major-pharma-tariffs-are-coming/
